peoplepill id: anne-f-luetkemeyer
AFL
United States of America
1 views today
1 views this week
Anne F. Luetkemeyer
American physician and infectious diseases researcher

Anne F. Luetkemeyer

The basics

Quick Facts

Intro
American physician and infectious diseases researcher
From
United States of America
is
Physician Infectious disease physician
Work field
Healthcare
Gender
Female
Place of birth
Baltimore, USA
Family
Siblings:
Julie Bowen
Education
Calvert School,
high school diploma
(-1984)
Stanford University,
Bachelor of Arts
(-1994)
Harvard Medical School,
Doctor of Medicine
(-1999)
University of California, San Francisco,
The details (from wikipedia)

Biography

Annie F. Luetkemeyer is a Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specialises in infectious diseases, in particular tuberculosis, HIV and viral hepatitis. During the 2019–20 coronavirus pandemic Luetkemeyer led a clinical trial into the use of remdesivir. She has also looked at treatment of COVID-19 as a co-infection with HIV.

Early life and education

Luetkemeyer was born in Baltimore, Maryland, to Suzanne Luetkemeyer (née Frey) and John Alexander Luetkemeyer Jr., a commercial real estate developer. She is the youngest of three sisters, one of whom is the actor, Julie Bowen. She grew up in Ruxton-Riderwood, Maryland. In 1984, Luetkeymer graduated from the Calvert School.

In 1994, Luetkemeyer received a AB in American Studies from Stanford University, where she graduated with distinction. In 1999, Luetkemeyer received an M.D. in Medicine from Harvard Medical School. In 2002 and 2003, she trained in internal medicine at the University of California, San Francisco. In 2006, Luetkemeyer completed advance training in clinical research, also at the University of California, San Francisco, and then completed an infectious disease fellowship in 2007.

Career

In 2012 Luetkemeyer called for investigations into the doses of HIV and TB. The recommendations had been re-written by the Food and Drug Administration in 2012. In a series of small studies in Europe it had been shown that Rifampicin, a drug used to treat tuberculosis, could limit the effectiveness of Efavirenz, a drug used to treat HIV. The drugs interact through a liver enzyme (cytochrome P450), which is produced at elevated levels in patients who take Rifampicin, but breaks down the Efavirenz. To overcome this, the 2012 Food and Drug Administration recommendations proposed larger doses of Efavirenz. Luetkemeyer argued that the recommendations were not appropriate for all populations in the United States; and in particular, may result in more drug toxicity. She showed that increasing the dosage of Efavirenz may result in most side effects – as well as coming at a greater financial cost.

During the 2019–20 coronavirus pandemic, Luetkemeyer led investigations into potential therapies for coronavirus disease. She is a member of the University of California, San Francisco cross-campus coronavirus disease task force. In line with most official advice, Luetkemeyer called for older people and tose with pre-existing conditions to be more careful during the outbreak, as the virus "taxes all organ systems". Luetkemeyer studied wihch coronavirus disease patients were most likely to benefit from treatment, when during their illness was most beneficial for treatment to occur and which types of treatment (antivirals or anti-inflammatories) were most appropriate. As well as studying researching potential treatment pathways, she has outlined what pre- and post exposure prophylaxis healthcare workers and household contacts can practise to prevent disease spread. In an effort to dispel any misinformation, Luetkemeyer has called for more randomized controlled trials to assess the impact of hydroxychloroquine, particularly as it can cause harmful side effects. She is leading a clinical trial into the use of the drug remdesivir. The San Francisco General Hospital SARS-CoV-2 guidelines only recommend treatment if patients are hospitalised or have strong risk factors for progression into severe disease. As of March 2020, the guidelines included remdesivir, or hydroxychloroquine if remdesivir was not feasible.

Selected works and publications

The contents of this page are sourced from Wikipedia article on 25 Apr 2020. The contents are available under the CC BY-SA 4.0 license.
Lists
Anne F. Luetkemeyer is in following lists

By field of work

Famous American people in healthcare and medicine

Gender: Female

By work and/or country

Famous American Physicians

Gender: Female

Famous American Infectious disease physicians

Gender: Female

By category

Harvard University alumni

Harvard University alumni

University of California, San Francisco alumni

University of California, San Francisco alumni

University of California, San Francisco faculty

University of California, San Francisco faculty
comments so far.
Comments
From our partners
Sponsored
Reference sources
References
https://www.kqed.org/perspectives/201601134791/hepatitis-c-is-curable
https://www.baltimoresun.com/entertainment/bs-sm-julie-bowen-profile-20100902-story.html
https://issuu.com/calvertschoolmd/docs/reflections_proof_5
https://www.iasusa.org/faculty/anne-f-luetkemeyer-md/
https://profiles.ucsf.edu/annie.luetkemeyer
https://www.ucsf.edu/news/2012/07/12389/ucsf-sfgh-researchers-call-change-new-fda-recommendation-hiv-and-tb-drug-doses
https://www.the-hospitalist.org/hospitalist/article/219602/coronavirus-updates/treatment-options-covid-19-dr-annie-luetkemeyer
https://www.sciencemag.org/news/2020/04/trials-drugs-prevent-coronavirus-infection-begin-health-care-workers
https://hividgm.ucsf.edu/covid-19/about-cross-campus-infectious-disease-covid-19-task-force
https://www.nytimes.com/2020/03/14/health/coronavirus-elderly-protection.html
https://www.nationalgeographic.co.uk/science-and-technology/2020/03/what-scientists-do-and-dont-know-about-treating-coronavirus
Anne F. Luetkemeyer
arrow-left arrow-right instagram whatsapp myspace quora soundcloud spotify tumblr vk website youtube pandora tunein iheart itunes